CLAIMS

1. A composition comprising
    i) a GLP-1 agonist,
    ii) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) and
    iii) a hydrotrope, wherein the hydrotrope is nicotinamide.

2. The composition of claim 1, wherein the ratio of salt of NAC/hydrotrope (w/w) is 0.5-10, such as 0.5-8 or such as 0.5-5.

3. The composition according claim 1 or claim 2, wherein the composition further comprises a lubricant selected from magnesium stearate and glyceryl dibehenate.

4. The composition according to any of the previous claims, wherein the GLP-1 agonist comprises at least one albumin binding substituent.

5. The composition according to any of the previous claims, wherein the GLP-1 agonist comprises a fatty acid or fatty diacid.

6. The composition according to any of the previous claims, wherein the GLP-1 agonist is selected from the group consisting of: liraglutide, semaglutide, GLP-1 agonist B and GLP-1 agonist C.

7. The composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) is a sodium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC).

8. The composition according to any of the previous claims, wherein the composition is a solid composition.

9. The composition according to any of the previous claims consisting of:
    i) a GLP-1 agonist, such as Semaglutide, GLP-1 agonist B or GLP-1 agonist C;
    ii) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), such as a sodium salt of NAC (SNAC);
    iii) nicotinamide; and
    iv) a lubricant.

10. The composition according to any of the previous claims, wherein a dose unit comprises 0.1-50 mg of the GLP-1 agonist.

11. The composition according to any of the previous claims, wherein a unit dosage comprises
    i) 0.1-30 mg, such as 0.1-20 mg GLP-1 agonist, such as Semaglutide, GLP-1 agonist B or GLP-1 agonist C;
    ii) 50-600 mg salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), such as a sodium salt of NAC (SNAC);
    iii) 20-200 mg nicotinamide; and
    iv) 0-10 mg lubricant.

12. The composition according to any of the previous claims wherein the composition is a pharmaceutical composition for oral administration.

13. Use of a composition according to any of the previous claims in the manufacture of a pharmaceutical composition for use in treating diabetes and/or obesity.

14. A method for producing a solid pharmaceutical composition comprising the steps of;
    i) obtaining a blend comprising a salt of NAC and a hydrotrope, wherein the hydrotrope is nicotinamide,
    ii) co-processing the blend of i), and
    iii) admixing the extrudate of ii) with an active pharmaceutical ingredient and optionally any further excipients,
    iv) preparing said solid pharmaceutical composition using the product of iii).

15. A method for producing a solid pharmaceutical composition comprising the steps of;
    i) obtaining a blend comprising a salt of NAC and a hydrotrope, wherein the hydrotrope is nicotinamide,
    ii) heat melt extruding the blend of i),
    iii) milling the extrudate of ii),
    iv) admixing the product of iii) with an active pharmaceutical ingredient and optionally any further excipients, and
    v) preparing said solid pharmaceutical composition using the product of iv).

16. A method for producing a solid pharmaceutical composition comprising the steps of

i) obtaining a blend comprising a salt of NAC and a hydrotrope, wherein the hydrotrope is nicotinamide,

ii) heat melt extruding the blend of i),

iii) admixing the extrudate of ii) with an active pharmaceutical ingredient and optionally any further excipients, and

iv) preparing said solid pharmaceutical composition using the mixture of iii).